CAJ | 학술논문

目的：探讨左氧氟沙星治疗耐多药肺结核病(MDR-PTB)患者的近期临床疗效。方法将80例确诊为MDR-PTB患者随机分组为对照组和治疗组。其中，对照组40例采用3SEL2DZ/15EL2D方案治疗，治疗组40例采用3CmVL2DZ/15VL2D方案治疗。结果疗程结束时，治疗组的临床症疗效总有效率为85.0%，对照组的总有效率为62.5%，组间比较差异有统计学意义(P<0.05)，治疗组的临床疗效优于对照组；在治疗3个月和疗程结束时，治疗组的痰菌阴转率分别为67.5%和87.5%，对照组的痰菌阴转率分别为45.0%和67.5%，组间比较差异有统计学意义(P<0.05)，治疗组的痰菌阴转率大于对照组；在疗程结束时，治疗组的病灶吸收和空洞闭合好转率分别为92.5%和88.9%，对照组的病灶吸收和空洞闭合好转率分别为72.5%和68.6%，组间比较差异有统计学意义(P<0.05)，治疗组的病灶吸收和空洞闭合改善更加明显。在治疗期间，治疗组的不良反应发生率低于对照组，但是组间比较差异无统计学意义(P>0.05)。结论左氧氟沙星治疗MDR-PTB患者的临床疗效好，值得临床推广应用。
목적：탐토좌양불사성치료내다약폐결핵병(MDR-PTB)환자적근기림상료효。방법장80례학진위MDR-PTB환자수궤분조위대조조화치료조。기중，대조조40례채용3SEL2DZ/15EL2D방안치료，치료조40례채용3CmVL2DZ/15VL2D방안치료。결과료정결속시，치료조적림상증료효총유효솔위85.0%，대조조적총유효솔위62.5%，조간비교차이유통계학의의(P<0.05)，치료조적림상료효우우대조조；재치료3개월화료정결속시，치료조적담균음전솔분별위67.5%화87.5%，대조조적담균음전솔분별위45.0%화67.5%，조간비교차이유통계학의의(P<0.05)，치료조적담균음전솔대우대조조；재료정결속시，치료조적병조흡수화공동폐합호전솔분별위92.5%화88.9%，대조조적병조흡수화공동폐합호전솔분별위72.5%화68.6%，조간비교차이유통계학의의(P<0.05)，치료조적병조흡수화공동폐합개선경가명현。재치료기간，치료조적불량반응발생솔저우대조조，단시조간비교차이무통계학의의(P>0.05)。결론좌양불사성치료MDR-PTB환자적림상료효호，치득림상추엄응용。
Objective To investigate the short-term clinical effect of levofloxacin in the treatment of patients with multidrug resistant pulmonary tuberculosis (MDR-PTB). Methods Eighty patients with MDR-PTB were ran-domly divided into the control group and the treatment group, each with 40 cases. Therapy of 3SEL2DZ/15EL2D and 3CmVL2DZ/15VL2D were adopted in the control group and the treatment group, respectively. Results At the end of treatment process, the total effective rate of the treatment group was 85.0%, significantly higher than 62.5%in the con-trol group (P<0.05). The clinical effect of the treatment group was better than that of the control group. After 3 months and 18 months of treatment, the negative conversion rate of acid-fast bacilli sputum smear was 67.5%and 87.5%in treatment group, 45.0%and 67.5%in control group, respectively, with significant difference between the two groups (P<0.05). At the end of treatment process, the improvement rate of clinical symptoms of lesions absorption and cavity closure was 92.5%and 88.9%in treatment group, 72.5%and 68.6%in the control group, respectively, with statistical-ly significant difference between the two groups (P<0.05). In the treatment process, the incidence rate of adverse reac-tions in treatment group was lower than that of control group, but there was no statistically significant difference (P>0.05). Conclusion There is significant clinical effect of levofloxacin in treatment of patients with MDR-PTB. The therapy is worthy of clinical popularization and application.